Iridex Corp
IRIX Nasdaq· Electromedical & Electrotherapeutic Apparatus
Last close · Oct 23, 2026
$0.75
KIRA · Stoqly’s AI analyst, in plain words
- Iridex Corp had $52.7M of revenue in fiscal 2026, up 8.2% on the year before. Over five years, revenue changed +7.7% a year on average.
- Its operating margin was −4.9%, up 12.2 pts: of every 100 in sales, about −5 is left after running the business.
- Iridex Corp lost $4.4M in fiscal 2026.
- Free cash flow was −$2.3M in fiscal 2026, −4.3% of revenue.
Market cap
$13.0M
P/E
—
Revenue
$52.7M
Net income
−$4.4M
Free cash flow
−$2.3M
Operating margin
−4.9%
Iridex Corp in 30 seconds · fiscal 2026
Are sales growing?
+8.2%
Yes. Sales grew 8.2% last year.
Does it make a profit?
−8.4%
No. It lost money last year.
Does profit turn into cash?
−4.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Iridex Corp does
No business description yet.
- Fiscal year ends
- January 3, 2026
- Latest annual report
- 10-K · Apr 2, 2026
- Legal name
- IRIDEX CORP
- CIK
- 0001006045
Iridex Corp · IRIX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $53.9M | $57.0M | $51.9M | $48.7M | $52.7M |
| Revenue growth | 48.3% | 5.7% | −9.0% | −6.2% | 8.2% |
| Gross margin | 42.4% | 44.5% | 42.0% | 40.1% | 36.5% |
| Operating margin | −14.0% | −13.2% | −19.3% | −17.1% | −4.9% |
| Net income | −$5.2M | −$7.5M | −$9.6M | −$8.9M | −$4.4M |
| Net margin | −9.7% | −13.2% | −18.5% | −18.3% | −8.4% |
| Diluted EPS | −$0.34 | −$0.47 | −$0.59 | −$0.54 | −$0.26 |
| Cash | |||||
| Cash from operations | $8.2M | −$9.5M | −$6.7M | −$7.3M | −$2.1M |
| Capital expenditure | $0.2M | $0.3M | $0.1M | $0.0M | $0.1M |
| Free cash flow | $8.0M | −$9.8M | −$6.9M | −$7.3M | −$2.3M |
| FCF margin | 14.8% | −17.2% | −13.2% | −15.0% | −4.3% |
| Share count change | 11.4% | 3.4% | 1.2% | 1.9% | 3.0% |
| Debt and strength | |||||
| Cash and short-term investments | $23.9M | $13.9M | $7.0M | $2.4M | $6.0M |
| Debt incl. finance leases | — | — | — | $2.7M | — |
| Shareholders' equity | $23.3M | $17.2M | $9.5M | $2.1M | $4.9M |
| Current ratio | 3.3x | 2.9x | 2.1x | 1.4x | 1.9x |
| Interest coverage | — | — | — | −56.9x | −44.3x |
| Returns and quality | |||||
| Return on capital | — | — | — | −272.1% | — |
| Return on equity | −25.7% | −37.2% | −71.5% | −153.4% | −126.4% |
| Return on tangible equity | −26.0% | −52.8% | −138.4% | — | −149.2% |
| Piotroski F-score | 4 | 2 | 2 | 2 | 4 |
| Altman Z'' | −0.2 | −2.2 | −6.3 | −10.1 | −8.0 |
Insiders bought, 12 months
$0.7M
3 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Iridex Corp · IRIX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.75 a share, the company is worth $13.0M.
Source: SEC EDGAR XBRL filings (CIK 0001006045). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.